Aurobindo Pharma Limited

NSEI:AUROPHARMA Stock Report

Market Cap: ₹675.9b

Aurobindo Pharma Management

Management criteria checks 3/4

Aurobindo Pharma's CEO is Kambam Reddy, appointed in Jun 2006, has a tenure of 17.92 years. total yearly compensation is ₹37.41M, comprised of 51.3% salary and 48.7% bonuses, including company stock and options. directly owns 5.58% of the company’s shares, worth ₹37.68B. The average tenure of the management team and the board of directors is 9.3 years and 5 years respectively.

Key information

Kambam Reddy

Chief executive officer

₹37.4m

Total compensation

CEO salary percentage51.3%
CEO tenure17.9yrs
CEO ownership5.6%
Management average tenure9.3yrs
Board average tenure5yrs

Recent management updates

Recent updates

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Apr 10
Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Jan 14
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Dec 27
Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Sep 07
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Jun 14
Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

May 21
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Feb 11
Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Jan 09
Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

Nov 02
Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt

Jun 20
We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt

Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Apr 14
Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Aurobindo Pharma's (NSE:AUROPHARMA) Dividend Will Be ₹1.50

Feb 11
Aurobindo Pharma's (NSE:AUROPHARMA) Dividend Will Be ₹1.50

Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Jan 08
Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

These 4 Measures Indicate That Aurobindo Pharma (NSE:AUROPHARMA) Is Using Debt Reasonably Well

Nov 27
These 4 Measures Indicate That Aurobindo Pharma (NSE:AUROPHARMA) Is Using Debt Reasonably Well

Aurobindo Pharma's (NSE:AUROPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Nov 10
Aurobindo Pharma's (NSE:AUROPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Here's Why Shareholders May Want To Be Cautious With Increasing Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Pay Packet

Aug 19
Here's Why Shareholders May Want To Be Cautious With Increasing Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Pay Packet

Aurobindo Pharma's (NSE:AUROPHARMA) Shareholders Will Receive A Bigger Dividend Than Last Year

Aug 15
Aurobindo Pharma's (NSE:AUROPHARMA) Shareholders Will Receive A Bigger Dividend Than Last Year

CEO Compensation Analysis

How has Kambam Reddy's remuneration changed compared to Aurobindo Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

₹28b

Sep 30 2023n/an/a

₹23b

Jun 30 2023n/an/a

₹20b

Mar 31 2023₹37m₹19m

₹19b

Dec 31 2022n/an/a

₹20b

Sep 30 2022n/an/a

₹21b

Jun 30 2022n/an/a

₹24b

Mar 31 2022₹27m₹14m

₹26b

Dec 31 2021n/an/a

₹29b

Sep 30 2021n/an/a

₹52b

Jun 30 2021n/an/a

₹53b

Mar 31 2021₹23m₹20m

₹53b

Dec 31 2020n/an/a

₹54b

Sep 30 2020n/an/a

₹31b

Jun 30 2020n/an/a

₹30b

Mar 31 2020₹15m₹13m

₹28b

Dec 31 2019n/an/a

₹26b

Sep 30 2019n/an/a

₹26b

Jun 30 2019n/an/a

₹25b

Mar 31 2019₹15m₹13m

₹24b

Dec 31 2018n/an/a

₹23b

Sep 30 2018n/an/a

₹22b

Jun 30 2018n/an/a

₹24b

Mar 31 2018₹15m₹13m

₹24b

Compensation vs Market: Kambam's total compensation ($USD448.28K) is about average for companies of similar size in the Indian market ($USD572.52K).

Compensation vs Earnings: Kambam's compensation has increased by more than 20% in the past year.

CEO

Kambam Reddy (65 yo)

17.9yrs

Tenure

₹37,406,887

Compensation

Mr. Kambam Nityananda Reddy has been Vice Chairman of Aurobindo Pharma Limited since June 1, 2012 and serves as a Whole Time Director of Aurobindo Pharma Limited since December 26, 1986 and serves as Manag...

Leadership Team

NamePositionTenureCompensationOwnership
Kambam Reddy
Vice Chairman & MD17.9yrs₹37.41m5.58%
₹ 37.7b
Mettu Madan Reddy
Whole-Time Directorno data₹52.35m0.00034%
₹ 2.3m
Santhanam Subramanian
Chief Financial Officer9.8yrs₹21.06mno data
Sanjeev Dani
COO & Head of Formulations8.8yrsno datano data
S. Kumar
President of Technicalno datano datano data
Arvind Bothra
Head of Investor Relations & Corporate Communicationsno datano datano data
B. Reddy
Compliance Officer & Company Secretary7.9yrs₹4.76mno data
G. Prasad
Senior Vice President of Global Finance & Operationsno datano datano data
Sudhir Singhi
Head of Global Finance Operationsno datano datano data
A. Rama Rao
President of Corporate QAno datano data0.024%
₹ 165.0m
V. Handa
President of Chemical Researchno datano datano data
Gita Rao
Associate President of RAD- IIno data₹9.14m0%
₹ 0

9.3yrs

Average Tenure

62yo

Average Age

Experienced Management: AUROPHARMA's management team is seasoned and experienced (9.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kambam Reddy
Vice Chairman & MD37.4yrs₹37.41m5.58%
₹ 37.7b
Mettu Madan Reddy
Whole-Time Director17.7yrs₹52.35m0.00034%
₹ 2.3m
Makkapati Satakarni
President of Biologicsless than a yearno datano data
Penaka Venkata Reddy
Non-Executive Director37.4yrs₹500.00k3.07%
₹ 20.8b
Penaka Sarath Reddy
Non-Executive Director16.7yrs₹11.04mno data
Santanu Mukherjee
Independent Director1.3yrs₹200.00kno data
Deepali Pant Joshi
Directorno datano datano data
Savitha Mahajan
Additional Non-Executive Independent Director6.4yrs₹2.30mno data
Venkat Chalasani
Independent Director of Apitoria Pharma Private Limited1.1yrsno datano data
Mangalam Kumar
Independent Non-Executive Chairmanless than a yearno datano data
Girish Vanvari
Non-Executive Independent Director3.5yrs₹2.70mno data

5.0yrs

Average Tenure

63yo

Average Age

Experienced Board: AUROPHARMA's board of directors are considered experienced (5 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.